Lysine-3,4-Methylenedioxymethamphetamine

赖氨酸-3,4-亚甲二氧基甲基苯丙胺

Report date: 2025/08/14 10:17:29
NME

Base Information

Drug NameLysine-3,4-Methylenedioxymethamphetamine
Drug Alias NameLysine-MDMA
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors agonistsCentral nervous system stimulants
TargetsAdrenergic receptors
Therapy Area/IndicationsStress Disorders, Post-Traumatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Hospital Basel
China Registration ClassN/A

Develop Information

Active CompaniesSan Diego Veterans Healthcare SystemHealing BreakthroughJohns Hopkins University +[5] 
Inactive CompaniesN/A
Active IndicationsStress Disorders, Post-Traumatic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A